-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Oscar Health, Raises Price Target to $49

Benzinga·09/17/2026 12:19:55
语音播报
Barclays analyst Andrew Mok maintains Oscar Health (NYSE:OSCR) with a Overweight and raises the price target from $39 to $49.